We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

161 hedge funds and large institutions have $582M invested in Keros Therapeutics in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 30 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 30

3% less call options, than puts

Call options by funds: $10.8M | Put options by funds: $11.2M

5% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 40

1% less funds holding

Funds holding: 163 → 161 (-2)

2.39% less ownership

Funds ownership: 93.1% → 90.72% (-2.4%)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

71% less capital invested

Capital invested by funds: $2.03B → $582M (-$1.45B)

Holders
161
Holders Change
-2
Holders Change %
-1.23%
% of All Funds
2.12%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
38
Increased
74
Reduced
30
Closed
40
Calls
$10.8M
Puts
$11.2M
Net Calls
-$380K
Net Calls Change
-$4.32M

Top Buyers

1
B
Braidwell
Connecticut
+$61.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$33.5M
3
LCM
Lynx1 Capital Management
Puerto Rico
+$28.3M
4
NCM
Nantahala Capital Management
Connecticut
+$27.7M
5
MP
Mangrove Partners
Connecticut
+$23.4M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$49.2M
2
Alkeon Capital Management
Alkeon Capital Management
New York
-$41.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$31.4M
4
PBA
Paradigm Biocapital Advisors
New York
-$30.5M
5
OM
Opaleye Management
Massachusetts
-$23M
Name Holding Trade Value Shares
Change 		Change in
Stake
State of Wisconsin Investment Board
76
State of Wisconsin Investment Board
Wisconsin
$703K +$869K +16,714 +60%
RhumbLine Advisers
77
RhumbLine Advisers
Massachusetts
$647K +$20.3K +391 +1%
Manulife (Manufacturers Life Insurance)
78
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$639K +$1.22M +23,550 +140%
NIM
79
NEOS Investment Management
Connecticut
$565K +$410K +7,885 +28%
TE
80
Tema ETFs
New York
$565K +$1.85M +35,663 New
Two Sigma Investments
81
Two Sigma Investments
New York
$533K +$1.21M +23,342 +226%
Russell Investments Group
82
Russell Investments Group
United Kingdom
$527K -$3.59M -68,995 -67%
AA
83
ALPS Advisors
Colorado
$519K +$252K +4,851 +17%
Legal & General Group
84
Legal & General Group
United Kingdom
$506K +$148K +2,855 +10%
VOYA Investment Management
85
VOYA Investment Management
Georgia
$467K -$7.58M -145,806 -83%
DekaBank Deutsche Girozentrale
86
DekaBank Deutsche Girozentrale
Germany
$463K – – –
Connor, Clark & Lunn Investment Management (CC&L)
87
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$461K +$1.51M +29,146 New
BPC
88
Bryce Point Capital
New York
$445K +$1.46M +28,127 New
California State Teachers Retirement System (CalSTRS)
89
California State Teachers Retirement System (CalSTRS)
California
$445K +$39.9K +767 +3%
Deutsche Bank
90
Deutsche Bank
Germany
$427K +$439K +8,447 +46%
RAM
91
Readystate Asset Management
Illinois
$404K +$1.09M +20,920 +454%
SG Americas Securities
92
SG Americas Securities
New York
$388K +$1.27M +24,493 New
ACM
93
ADAR1 Capital Management
Texas
$368K -$21.9M -421,822 -95%
TRCT
94
Tower Research Capital (TRC)
New York
$364K +$1.1M +21,145 +1,150%
FRM
95
Fox Run Management
Connecticut
$352K +$835K +16,069 +262%
EAM
96
Erste Asset Management
Austria
$340K – – –
Two Sigma Advisers
97
Two Sigma Advisers
New York
$328K +$717K +13,800 +200%
Mirae Asset Global ETFs Holdings
98
Mirae Asset Global ETFs Holdings
Hong Kong
$303K +$72K +1,386 +8%
IIM
99
INTECH Investment Management
Florida
$299K +$441K +8,489 +82%
MIM
100
MetLife Investment Management
New Jersey
$286K +$53.4K +1,027 +6%
2 3
4
5 6

KROS Hedge Fund Activity: Q4 2024 in Review

161 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2024, worth a combined $582M — down 71% from $2.03B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of KROS and 38 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 74 added.

The largest buyer was Braidwell, adding an estimated $61.7M. The largest seller was Point72 Asset Management, cutting an estimated $49.2M.

  • 161 institutional investors held Keros Therapeutics (KROS) as of Q4 2024, down from 163 in Q3 2024.
  • Funds reported $582M of Keros Therapeutics stock for Q4 2024, down 71% quarter-over-quarter.
  • 38 funds opened new Keros Therapeutics positions in Q4 2024 and 40 closed out, a net change of -2 holders.
  • The largest Keros Therapeutics buyer in Q4 2024 was Braidwell, an estimated $61.7M added.
  • The largest Keros Therapeutics seller in Q4 2024 was Point72 Asset Management, an estimated $49.2M sold.

Based on aggregated 13F filings for Q4 2024.